Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Kimberly E. Vanover; David M. Weiner; Malath Makhay; Isaac Veinbergs; Luis R. Gardell; Jelveh Lameh; Andria L. Del Tredici; Fabrice Piu; Hans H. Schiffer; Thomas Ott; Ethan S. Burstein; Allan K Uldam; Mikkel B. Thygesen; Nathalie Schlienger; Carl Magnus Andersson; Thomas Son; Scott C. Harvey; Susan B. Powell; Mark A. Geyer; Bo-Ragner Tolf; Mark R. Brann; Robert E. Davis

doi:10.1124/jpet.105.097006

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist | Litlas